These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8725890)

  • 1. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Kinahan J; Sullivan LD
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):39-45; discussion 46-7. PubMed ID: 8725890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F; Perrotti M; Bastar A; Fair WR
    J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hormone therapy: the Canadian trials.
    Klotz L; Gleave M; Goldenberg SL
    Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
    Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
    Roach M
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant hormonal treatment before radical prostatectomy.
    Watson RB; Soloway MS
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):48-55; discussion 55-6. PubMed ID: 8725891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant hormonal therapy for prostate cancer].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.